Our study identifies a vulnerability of p53-null CLL cells with high sensitivity to ROS-generating agents, and suggests that PEITC may potentially be useful for clinical treatment of CLL with 17p deletion and p53 mutations. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.